Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

December 31, 2022

Conditions
Metabolic Syndrome X
Interventions
DIETARY_SUPPLEMENT

Astaxanthin

The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.

OTHER

Placebo

Matching placebo pill

Trial Locations (1)

92037

Altman Clinical and Translational Research Institute (ACTRI), San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT03310359 - Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects | Biotech Hunter | Biotech Hunter